Apollomics, Inc. (APLM)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on APLM

With Tiblio's Option Bot, you can configure your own wheel strategy including APLM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol APLM
  • Rev/Share 0.0227
  • Book/Share 0.0525
  • PB 115.4283
  • Debt/Equity 0.1986
  • CurrentRatio 1.3876
  • ROIC -6.5876

 

  • MktCap 6686289.0
  • FreeCF/Share -0.2744
  • PFCF -0.2631
  • PE -12.1631
  • Debt/Assets 0.0738
  • DivYield 0
  • ROE -2.105

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Apollomics, Inc. (APLM)

  • IPO Date 2021-11-26
  • Website https://www.apollomicsinc.com
  • Industry Biotechnology
  • CEO Dr. Guo-Liang Yu Ph.D.
  • Employees 13
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.